argenx SE ARGX 深 沪
交易中 07-01 10:27:48 美东时间
907.85
-19.920
-2.15%
华盛通- 最 高930.47
- 今 开930.00
- 成交量 7.00万股
- 最 低 906.13
- 昨 收 927.77
- 总市值 564.57亿
- 52周最高 934.6199
- 市盈率 静 46.25
- 换手率 0.11%
- 52周最低 554.59
- 委 比 -88.24%
- 总股本 6218.78万
- 历史最高 934.6199
- 量 比 1.46
- 振 幅 2.62%
- 历史最低 19.00
- 每 手 1
- 风险率 95.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股夜盘 | Bloom Energy涨8.37%，Intuitive Machines涨5.47%
Bloom Energy涨8.37%；Intuitive Machines涨5.47%；万国数据涨3.23%
今天 15:01
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
06-25 11:32
Okta To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG raised the price target for International Seaways Inc (NYSE:INSW) from $90 to $100. BTIG analyst Gregory ...
06-24 20:56
Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1180
Morgan Stanley analyst Matthew Harrison maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1170 to $1180.
06-24 20:50
If You Invested $100 In argenx Stock 5 Years Ago, You Would Have This Much Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 11.88% on an annualized basis producing an average annual return of 23.57%. Currently, argenx has a market capitalization of $55.90 billion. Buying $100 In ARGX: If an investor had bought $100 of ARGX stock 5 years ago, it wou...
06-12 05:15
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position: Analyst
Sanofi SA (NASDAQ:SNY) on Wednesday announced that it will discontinue its Phase 3 MOBILIZE study evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who had not responded to standard treatments. CIDP is a rare, acquired autoimmune disorder of the periphe...
06-11 21:09
美股大行评级 | 绩后暴跌，博通仍获11家大行上调目标价；CrowdStrike获21家大行集体上调目标价；Netskope、Veeva Systems惨遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Vivos Therapeutics"买入"评级，目标价从3美元升至3.1美元；富国银行：维持Veeva Systems"超配"评级，目标价从317美元升至320美元
06-05 11:33
